Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

NCT00333788 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

BIOLOGICAL: Certolizumab pegol (CDP870)

Sponsor

UCB Pharma